Drug Trial Radar · NCT05336071
The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 12, 2022
Primary completion
May 26, 2022
Study completion Jun 2, 2022
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 24 healthy male subjects. Subjects will receive INS068 injection on Day1 and Day8.
Conditions
- Diabetes Mellitus
Interventions
INS068 injectionDrug
Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
INS068 injectionDrug
Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed serum concentration (Cmax) of INS068 injectionTime frame: from Day1 to Day5 after the first cycle(each cycle is 5 days) and from Day8 to Day12 after the second cycle(each cycle is 5 days)
- Area under the plasma concentration versus time curve (AUC0-t) of INS068 injectionTime frame: from Day1 to Day5 after the first cycle(each cycle is 5 days) and from Day8 to Day12 after the second cycle(each cycle is 5 days)
- Area under the plasma concentration versus time curve (AUC0-inf ) of INS068 injectionTime frame: from Day1 to Day5 after the first cycle(each cycle is 5 days) and from Day8 to Day12 after the second cycle(each cycle is 5 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Qian Foshan Hospital of Shandong Province
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.